Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenichi Suda

Showing results (101-110 of 127) with videos related to

Pageof 13
Sort By:
Surgical Case Reports|June 28, 2019
Primary pulmonary mucosa-associated lymphoid tissue lymphoma with amyloid light chain-type amyloidosisShuta Ohara, Kenji Tomizawa, Shigeki Shimizu, et al.
Clinical Lung Cancer|April 17, 2012
Knockdown of the epidermal growth factor receptor gene to investigate its therapeutic potential for the treatment of non-small-cell lung cancersKazuhiko Shien, Tsuyoshi Ueno, Kazunori Tsukuda, et al.
JTO Clinical and Research Reports|May 16, 2022
Presence of a Ground-Glass Opacity Component Is the True Prognostic Determinant in Clinical Stage I NSCLCAkira Hamada, Kenichi Suda, Toshio Fujino, et al.
Lung Cancer (Amsterdam, Netherlands)|June 5, 2017
Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cellsKenichi Suda, Leslie Rozeboom, Christopher J Rivard, et al.
Molecular Oncology|June 8, 2020
Neuroendocrine subtypes of small cell lung cancer differ in terms of immune microenvironment and checkpoint molecule distributionDavid Dora, Christopher Rivard, Hui Yu, et al.
Lung Cancer (Amsterdam, Netherlands)|December 12, 2018
Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro studyTakamasa Koga, Yoshihisa Kobayashi, Kenji Tomizawa, et al.
Journal of Surgical Oncology|January 31, 2022
Loss of STING expression is prognostic in non-small cell lung cancerZoltan Lohinai, David Dora, Charles Caldwell, et al.
JTO Clinical and Research Reports|March 20, 2026
Tolerance and Resistance to Targeted Therapy in NSCLC: Emerging Concepts and StrategiesMontse Sanchez-Cespedes, William W Lockwood, Kenichi Suda, et al.
JTO Clinical and Research Reports|February 24, 2025
Clinical Significance of Perioperative Minimal Residual Disease Detected by Circulating Tumor DNA in Patients With Lung Cancer With a Long Follow-up Data: An Exploratory StudyShuta Ohara, Kenichi Suda, Sumedha Sudhaman, et al.
Journal of Experimental & Clinical Cancer Research : CR|March 12, 2022
HDAC7 promotes NSCLC proliferation and metastasis via stabilization by deubiquitinase USP10 and activation of β-catenin-FGF18 pathwayKai Guo, Zhiqiang Ma, Yujiao Zhang, et al.
Pageof 13

Showing results (101-110 of 127) with videos related to

Sort By:
Pageof 13
Surgical Case Reports|June 28, 2019
Primary pulmonary mucosa-associated lymphoid tissue lymphoma with amyloid light chain-type amyloidosisShuta Ohara, Kenji Tomizawa, Shigeki Shimizu, et al.
Clinical Lung Cancer|April 17, 2012
Knockdown of the epidermal growth factor receptor gene to investigate its therapeutic potential for the treatment of non-small-cell lung cancersKazuhiko Shien, Tsuyoshi Ueno, Kazunori Tsukuda, et al.
JTO Clinical and Research Reports|May 16, 2022
Presence of a Ground-Glass Opacity Component Is the True Prognostic Determinant in Clinical Stage I NSCLCAkira Hamada, Kenichi Suda, Toshio Fujino, et al.
Lung Cancer (Amsterdam, Netherlands)|June 5, 2017
Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cellsKenichi Suda, Leslie Rozeboom, Christopher J Rivard, et al.
Molecular Oncology|June 8, 2020
Neuroendocrine subtypes of small cell lung cancer differ in terms of immune microenvironment and checkpoint molecule distributionDavid Dora, Christopher Rivard, Hui Yu, et al.
Lung Cancer (Amsterdam, Netherlands)|December 12, 2018
Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro studyTakamasa Koga, Yoshihisa Kobayashi, Kenji Tomizawa, et al.
Journal of Surgical Oncology|January 31, 2022
Loss of STING expression is prognostic in non-small cell lung cancerZoltan Lohinai, David Dora, Charles Caldwell, et al.
JTO Clinical and Research Reports|March 20, 2026
Tolerance and Resistance to Targeted Therapy in NSCLC: Emerging Concepts and StrategiesMontse Sanchez-Cespedes, William W Lockwood, Kenichi Suda, et al.
JTO Clinical and Research Reports|February 24, 2025
Clinical Significance of Perioperative Minimal Residual Disease Detected by Circulating Tumor DNA in Patients With Lung Cancer With a Long Follow-up Data: An Exploratory StudyShuta Ohara, Kenichi Suda, Sumedha Sudhaman, et al.
Journal of Experimental & Clinical Cancer Research : CR|March 12, 2022
HDAC7 promotes NSCLC proliferation and metastasis via stabilization by deubiquitinase USP10 and activation of β-catenin-FGF18 pathwayKai Guo, Zhiqiang Ma, Yujiao Zhang, et al.
Pageof 13